Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIO NASDAQ:FEMY NASDAQ:STRR NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$0.55-4.0%$0.69$0.50▼$1.55$24.45M1.24173,314 shs116,368 shsFEMYFemasys$0.82-1.2%$0.90$0.69▼$1.80$26.97M-2.56153,605 shs136,252 shsSTRRStar Equity$2.02-0.5%$2.05$1.72▼$4.74$6.55M0.9416,931 shs26,397 shsVVOSVivos Therapeutics$5.18+19.6%$3.85$1.97▼$7.95$25.50M7.03428,007 shs981,899 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth-4.03%-15.56%-22.56%-26.68%-49.08%FEMYFemasys-1.16%-8.93%-13.71%-29.34%-27.47%STRRStar Equity-0.05%-3.81%+2.54%-9.42%-58.09%VVOSVivos Therapeutics+19.63%-1.15%+35.25%+89.74%+125.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRIODarioHealth1.8623 of 5 stars3.31.00.00.00.00.81.3FEMYFemasys2.7852 of 5 stars3.55.00.00.00.02.50.6STRRStar Equity3.1816 of 5 stars3.54.00.00.00.01.71.3VVOSVivos Therapeutics0.4445 of 5 stars1.32.00.00.01.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.67Moderate Buy$2.00263.70% UpsideFEMYFemasys 3.00Buy$8.67957.43% UpsideSTRRStar Equity 3.00Buy$5.00147.52% UpsideVVOSVivos Therapeutics 2.50Moderate Buy$4.82-7.01% DownsideCurrent Analyst Ratings BreakdownLatest STRR, FEMY, DRIO, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/15/2025STRRStar EquityMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$28.03M0.87N/AN/A$2.11 per share0.26FEMYFemasys$1.70M15.69N/AN/A$0.10 per share8.20STRRStar Equity$53.36M0.12$0.32 per share6.23$10.98 per share0.18VVOSVivos Therapeutics$15.03M2.03N/AN/A$1.35 per share3.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$42.75M-$0.56N/AN/AN/A-159.80%-65.81%-38.41%8/6/2025 (Estimated)FEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)STRRStar Equity-$10.44M-$3.43N/AN/AN/A-16.43%-8.24%-3.48%8/12/2025 (Estimated)VVOSVivos Therapeutics-$11.14M-$1.73N/AN/AN/A-76.82%-170.43%-77.82%8/13/2025 (Estimated)Latest STRR, FEMY, DRIO, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DRIODarioHealth-$0.11N/AN/AN/A$6.91 millionN/A8/14/2025N/AFEMYFemasys-$0.18N/AN/AN/AN/AN/A8/13/2025Q2 2025VVOSVivos Therapeutics-$0.39N/AN/AN/A$3.37 millionN/A8/12/2025Q2 2025STRRStar Equity-$0.26N/AN/AN/A$16.75 millionN/A5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/14/2025Q1 2025STRRStar Equity-$0.25-$0.52-$0.27-$0.37$16.35 million$12.92 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.262.011.77FEMYFemasys0.020.930.54STRRStar Equity0.221.420.88VVOSVivos TherapeuticsN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%FEMYFemasys65.27%STRRStar Equity3.84%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipDRIODarioHealth11.20%FEMYFemasys11.54%STRRStar Equity33.51%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth20044.46 million39.48 millionOptionableFEMYFemasys3032.53 million28.77 millionNot OptionableSTRRStar Equity4603.23 million2.15 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableSTRR, FEMY, DRIO, and VVOS HeadlinesRecent News About These CompaniesVivos Therapeutics Adds to Management Team to Support Expansion and GrowthJuly 30 at 10:47 AM | finance.yahoo.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comVivos Therapeutics Secures CMS Approval for VidaSleep™ Oral Appliance, Expanding Access to Sleep Apnea TreatmentJuly 1, 2025 | quiverquant.comQNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | finance.yahoo.comNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | globenewswire.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finance.yahoo.comVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Expanding OSA Diagnostic and Treatment CapabilitiesJune 11, 2025 | quiverquant.comQVivos Therapeutics Secures $1.1M Convertible NoteMay 23, 2025 | tipranks.comEarnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock risesMay 17, 2025 | uk.investing.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 17, 2025 | finanznachrichten.deVivos Therapeutics Inc (VVOS) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and FDA ...May 17, 2025 | finance.yahoo.comVivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial ChallengesMay 16, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTRR, FEMY, DRIO, and VVOS Company DescriptionsDarioHealth NASDAQ:DRIO$0.55 -0.02 (-4.03%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$0.54 -0.01 (-1.62%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Femasys NASDAQ:FEMY$0.82 -0.01 (-1.16%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.81 -0.01 (-1.05%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Star Equity NASDAQ:STRR$2.02 -0.01 (-0.49%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.Vivos Therapeutics NASDAQ:VVOS$5.18 +0.85 (+19.63%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.18 0.00 (-0.10%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
